LSPG(SZ:301111)2023-04-27 16:00Financial Performance - The company's revenue for Q1 2023 was ¥79,304,090.52, representing a 31.78% increase compared to ¥60,179,981.94 in the same period last year[5] - Net profit attributable to shareholders was ¥14,816,687.61, up 13.13% from ¥13,096,502.82 year-on-year[5] - The net profit after deducting non-recurring gains and losses increased by 49.30%, reaching ¥10,825,582.19 compared to ¥7,251,132.34 in the previous year[5] - The company's basic and diluted earnings per share both increased by 12.50%, reaching ¥0.09 compared to ¥0.08 in the same period last year[5] - Net profit for Q1 2023 was ¥14,816,637.93, representing a 13.1% increase from ¥13,096,502.82 in Q1 2022[22] - The total comprehensive income attributable to the parent company was CNY 14,816,687.61, an increase from CNY 13,096,502.82 in the previous period, representing a growth of approximately 13.1%[23] Operating Costs and Expenses - The company experienced a 45.31% increase in operating costs, totaling ¥25,924,479.77, primarily due to rising prices of raw materials for traditional Chinese medicine[8] - Operating costs rose by 45.31% year-on-year, exceeding the revenue growth rate[14] - Total operating costs for Q1 2023 were ¥66,187,704.59, up 26.9% from ¥52,114,398.22 in the same period last year[21] - Research and development expenses for Q1 2023 amounted to ¥2,165,209.75, a decrease of 20.1% compared to ¥2,711,800.92 in Q1 2022[22] Cash Flow and Liquidity - The company reported a significant decrease in net cash flow from operating activities, which was -¥20,027,562.27, a decline of 262.79% from ¥12,302,965.05 in the same period last year[9] - Cash inflow from operating activities totaled CNY 77,481,648.86, down from CNY 81,267,104.24, indicating a decrease of about 4.5%[25] - Cash outflow from operating activities increased to CNY 97,509,211.13 from CNY 68,964,139.19, representing an increase of approximately 41.3%[25] - Net cash flow from investing activities was negative at CNY -6,966,477.17, an improvement from CNY -352,087,471.95 in the previous period[26] - Cash and cash equivalents decreased to ¥67,080,839.20 from ¥81,320,931.29, a decline of 17.4%[18] - The company reported cash inflow from investment activities of CNY 55,895,850.70, down from CNY 65,358,093.66, indicating a decrease of about 3.5%[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥838,928,029.06, down 2.12% from ¥857,063,372.44 at the end of the previous year[5] - Total liabilities decreased to ¥65,440,243.43 in Q1 2023 from ¥98,392,224.74 in Q1 2022, a reduction of 33.5%[19] - The company's equity attributable to shareholders rose to ¥773,487,858.61 from ¥758,671,171.00, an increase of 1.9%[19] Shareholder Information - The total number of common stock shareholders at the end of the reporting period was 15,968[11] - The top shareholder, Guangdong Jino Health Technology Co., Ltd., holds 45% of the shares, totaling 72 million shares[11] - The total number of restricted shares at the end of the reporting period was 89,861,520 shares, with no shares released during the period[13] Joint Ventures and Expansion - The company established a joint venture, Shantou Beikang Enze Health Management Co., Ltd., with a registered capital of RMB 10 million, where the company holds a 70% stake[14] - The joint venture aims to expand into the maternal and child health management service industry[14] - The first Baby Bella maternal and child care center in Shantou is currently under renovation and is expected to start trial operations in the second half of the year[15] Other Income and Changes - The company reported a 74.61% decrease in other income, which fell to ¥898,626.82 from ¥3,539,913.60 in the previous year[8] - The company's intangible assets increased by 286.07%, amounting to ¥30,217,137.67, due to the need for land price payments[8] Preliminary Report - The first quarter report was not audited, indicating that the figures are preliminary and subject to change[27]